Our primary objective is to demonstrate the feasibility of utilizing a novel penicillin
allergy questionnaire in the PED to identify a low-risk group of patients who will complete
an oral challenge in the PED to test for an IgE-mediated allergic reaction. This project
began as a single site feasibility study, however it has now transitioned to include 2 other
collaborative sites for enrollment. We have entered into a single IRB with 1 of the
collaborative sites. The other site has elected to do their own IRB.
Our secondary objective is to examine whether health care outcomes and prescription-related
costs are comparable between children who are de-labeled as penicillin allergic after an oral
challenge compared to a standard of care group who are not challenged in the PED.